Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Eribulin in HER2- Metastatic Breast Cancer
NCT04061863Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2019
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in breast cancer (2 cohorts), sponsored by Seoul National University Hospital. Primary endpoint: Progression-Free Survival Rate at 6 months. Status: unknown.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04061863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061863.